{
    "2021-07-21": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Why AbbVie (ABBV) is a Great Dividend Stock Right Now",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "dividend",
                        "great"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Here's Why AbbVie (ABBV) is a Strong Momentum Stock",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "momentum",
                        "strong"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Venclexta",
                        "breakthrough",
                        "therapy",
                        "MDS"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Venetoclax (VENCLEXTAÂ®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)",
                "features": {
                    "keywords": [
                        "Venetoclax",
                        "VENCLEXTA",
                        "FDA",
                        "breakthrough",
                        "therapy",
                        "MDS"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}